UB Paderborn / Katalog / Suche / in CDI

Survivin minigene DNA vaccination is effective against neuroblastoma

International journal of cancer, 2009-07, Vol.125 (1), p.104-114

2009

Volltextzugriff (PDF)

A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity

Molecular cancer therapeutics, 2008-07, Vol.7 (7), p.2241-2251

2008

Volltextzugriff (PDF)

Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma

Molecular cancer therapeutics, 2009-08, Vol.8 (8), p.2392-2401

2009

Volltextzugriff (PDF)

NK cells engineered to express a GD 2 ‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

Journal of cellular and molecular medicine, 2012-03, Vol.16 (3), p.569-581

2012

Volltextzugriff (PDF)

NK cells engineered to express a GD2‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

Journal of cellular and molecular medicine, 2012-03, Vol.16 (3), p.569-581

2012

Volltextzugriff (PDF)

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma

Cancer Immunology, Immunotherapy, 2015-05, Vol.64 (5), p.621-634

2015

Volltextzugriff (PDF)

Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma

Cancer letters, 2013-05, Vol.331 (2), p.167-173

2013

Volltextzugriff (PDF)

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response

Cancer immunology, immunotherapy, 2013-06, Vol.62 (6), p.999-1010

2013

Volltextzugriff (PDF)

Abstract LB-155: A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.LB-155-LB-155

2011

Volltextzugriff (PDF)

Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice

Cancer Immunology, Immunotherapy, 2015-10, Vol.64 (10), p.1215-1227

2015

Volltextzugriff (PDF)

Abstract 2808: GD2-specific genetically engineered NK cell therapy is effective in a drug-resistant neuroblastoma xenograft mouse model

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2808-2808

2014

Volltextzugriff (PDF)

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity

Journal of molecular medicine (Berlin, Germany), 2013-04, Vol.91 (4), p.459-472

2013

Volltextzugriff (PDF)

Xenogeneic tyrosine hydroxylase DNA vaccination is effective against neuroblastoma (48.14)

The Journal of immunology (1950), 2007-04, Vol.178 (1_Supplement), p.S77-S77

2007

Volltextzugriff (PDF)

Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3571-3571

2023

Volltextzugriff (PDF)

Abstract 1800: 4-HPR (fenretinide) sensitizes human neuroblastoma cells for antibody-independent and ch14.18-mediated NK cell killing

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1800-1800

2011

Volltextzugriff (PDF)

Abstract 1808: Neuroblastoma cell lines established from progressive disease that exhibit partial or multi drug resistance are highly sensitive to chimeric receptor scFv(ch14.18)-zeta mediated NK cell killing

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1808-1808

2011

Volltextzugriff (PDF)

Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells

Cancer research (Chicago, Ill.), 2007-03, Vol.67 (5), p.2331-2338

2007

Volltextzugriff (PDF)

Abstract A28: Generation and characterization of anti-idiotype antibody ganglidiomab as GD2 surrogate for immunotherapy of neuroblastoma

Cancer research (Chicago, Ill.), 2013-01, Vol.73 (1_Supplement), p.A28-A28

2013

Volltextzugriff (PDF)

Eradication of CD19+ Leukemia by Targeted Calicheamicin θ

Bioconjugate chemistry, 2009-08, Vol.20 (8), p.1587-1594

2009

Volltextzugriff (PDF)

Abstract 4758: A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4758-4758

2010

Volltextzugriff (PDF)

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD sub(2)-specific anti-neuroblastoma immune response

Cancer Immunology, Immunotherapy, 2013-06, Vol.62 (6), p.999-1010

2013

Volltextzugriff (PDF)

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response

Cancer Immunology, Immunotherapy, 2013-06, Vol.62 (6), p.999-1010

2013

Volltextzugriff (PDF)

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD^sub 2^-specific anti-neuroblastoma immune response

Cancer immunology, immunotherapy, 2013-06, Vol.62 (6), p.999

2013

Volltextzugriff (PDF)

Systematic amino acid substitutions improved efficiency of GD2 -peptide mimotope vaccination against neuroblastoma

European journal of cancer (1990), 2009-11, Vol.45 (16), p.2915-2921

2009

Volltextzugriff (PDF)

Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases

Cancer research (Chicago, Ill.), 2006-11, Vol.66 (21), p.10567-10575

2006

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Survivin minigene DNA vaccination is effective against neuroblastoma

A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity

Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma

NK cells engineered to express a GD 2 ‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

NK cells engineered to express a GD2‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma

Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response

Abstract LB-155: A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine

Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice

Abstract 2808: GD2-specific genetically engineered NK cell therapy is effective in a drug-resistant neuroblastoma xenograft mouse model

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity

Xenogeneic tyrosine hydroxylase DNA vaccination is effective against neuroblastoma (48.14)

Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

Abstract 1800: 4-HPR (fenretinide) sensitizes human neuroblastoma cells for antibody-independent and ch14.18-mediated NK cell killing

Abstract 1808: Neuroblastoma cell lines established from progressive disease that exhibit partial or multi drug resistance are highly sensitive to chimeric receptor scFv(ch14.18)-zeta mediated NK cell killing

Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells

Abstract A28: Generation and characterization of anti-idiotype antibody ganglidiomab as GD2 surrogate for immunotherapy of neuroblastoma

Eradication of CD19+ Leukemia by Targeted Calicheamicin θ

Abstract 4758: A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD sub(2)-specific anti-neuroblastoma immune response

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD^sub 2^-specific anti-neuroblastoma immune response

Systematic amino acid substitutions improved efficiency of GD2 -peptide mimotope vaccination against neuroblastoma

Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases

Suchergebnisse filtern